{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T12:29:36Z","timestamp":1793104176621,"version":"4.5.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,11,13]],"date-time":"2020-11-13T00:00:00Z","timestamp":1605225600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,11,13]],"date-time":"2020-11-13T00:00:00Z","timestamp":1605225600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Shanghai Municipal Key Clinical Specialty","award":["shslczdzk01102"],"award-info":[{"award-number":["shslczdzk01102"]}]},{"name":"Ministry of Science and Technology of the People\u2018s Republic of China under Grant : National Key Project of \u201813th five-year\u2019 Infectious Diseases Program","award":["2017ZX10202101"],"award-info":[{"award-number":["2017ZX10202101"]}]},{"name":"Fudan University under Grant","award":["RC-QT-2019-01"],"award-info":[{"award-number":["RC-QT-2019-01"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Tumour subtype has a significant effect on bone metastasis in breast cancer, but population-based estimates of the prognosis of patients with bone metastases at breast cancer diagnosis are lacking. The aim of this study was to analyse the influence of tumour subtype and other factors on the prognosis and survival of patients with bone metastases of breast cancer.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Using the Surveillance, Epidemiology, and End Results (SEER) Program data from 2012 to 2016, a retrospective cohort study was conducted to investigate stage IV breast cancer patients with bone metastases. Stage IV patient characteristics according to subtype were compared using chi-square tests. Overall survival (OS) and prognostic factors were compared using the Kaplan-Meier method and the Cox proportional hazards model, respectively.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 3384 stage IV patients were included in this study; 63.42% were HR+\/HER2-, 19.86% were HR+\/HER2+, 9.34% were HR\u2212\/HER2-, and 7.39% were HR\u2212\/HER2+. The median OS for the whole population was 38\u2009months, and 33.9% of the patients were alive at 5 years. The median OS and five-year survival rate were significantly different among stage IV breast cancer patients with different molecular subtypes (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.05). Multivariate Cox regression analysis showed that age of 55\u201359 (HR\u2009=\u20091.270), black race (HR\u2009=\u20091.317), grade III or IV (HR\u2009=\u20091.960), HR\u2212\/HER2- (HR\u2009=\u20092.808), lung metastases (HR\u2009=\u20091.378), liver metastases (HR\u2009=\u20092.085), and brain metastases (HR\u2009=\u20091.903) were independent risk factors for prognosis; married status (HR\u2009=\u20090.819), HR+\/HER2+ (HR\u2009=\u20090.631), HR\u2212\/HER2+ (HR\u2009=\u20090.716), insurance (HR\u2009=\u20090.587) and surgery (HR\u2009=\u20090.504) were independent protection factors of prognosis. There was an interaction between the HR+\/HER2+ subtype and other metastases (except bone metastases, HR\u2009=\u20090.694, 95% CI: 0.485\u20130.992), but the interaction between race and subtype did not reach significance for prognosis.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>There were substantial differences in OS according to tumour subtype. In addition to tumour subtype, other independent predictors of OS were age at diagnosis, race, marital status, insurance, grade, surgery and visceral metastases. There was an interaction between the HR+\/HER2+ subtype and other metastases (except bone metastases) for prognosis. Tumour subtype, as a significant prognostic factor, warrants further investigation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12885-020-07593-8","type":"journal-article","created":{"date-parts":[[2020,11,13]],"date-time":"2020-11-13T08:03:24Z","timestamp":1605254604000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["Prognostic factors and survival according to tumour subtype in women presenting with breast cancer bone metastases at initial diagnosis: a SEER-based study"],"prefix":"10.1186","volume":"20","author":[{"given":"Xiao","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoli","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yinzhong","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,11,13]]},"reference":[{"key":"7593_CR1","unstructured":"Surveillance Epidemiology, and end results program. Introduction to Breast Cancer https:\/\/www.training.seer.cancer.gov\/breast\/intro\/. Accessed 9 July 2019."},{"key":"7593_CR2","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.semcancer.2015.08.009","volume":"35","author":"S Kimbung","year":"2015","unstructured":"Kimbung S, Loman N, Hedenfalk I. Clinical and molecular complexity of breast cancer metastases. Semin Cancer Biol. 2015;35:85\u201395.","journal-title":"Semin Cancer Biol"},{"issue":"2","key":"7593_CR3","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1007\/s10549-011-1475-5","volume":"129","author":"M Yong","year":"2011","unstructured":"Yong M, Jensen AO, Jacobsen JB, Norgaard M, Fryzek JP, Sorensen HT. Survival in breast cancer patients with bone metastases and skeletal-related events: a population-based cohort study in Denmark (1999-2007). Breast Cancer Res Treat. 2011;129(2):495\u2013503.","journal-title":"Breast Cancer Res Treat"},{"key":"7593_CR4","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.critrevonc.2017.04.008","volume":"115","author":"JJ Body","year":"2017","unstructured":"Body JJ, Quinn G, Talbot S, Booth E, Demonty G, Taylor A, et al. Systematic review and meta-analysis on the proportion of patients with breast cancer who develop bone metastases. Crit Rev Oncol Hematol. 2017;115:67\u201380.","journal-title":"Crit Rev Oncol Hematol"},{"issue":"1","key":"7593_CR5","doi-asserted-by":"publisher","first-page":"20081","DOI":"10.1038\/s41598-019-55765-9","volume":"9","author":"S Lopez-Tarruella","year":"2019","unstructured":"Lopez-Tarruella S, Escudero MJ, Pollan M, et al. Survival impact of primary tumor resection in de novo metastatic breast cancer patients (GEICAM\/El Alamo registry). Sci Rep. 2019;9(1):20081 Published 2019 Dec 27.","journal-title":"Sci Rep"},{"issue":"11","key":"7593_CR6","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1634\/theoncologist.2018-0085","volume":"23","author":"A Parkes","year":"2018","unstructured":"Parkes A, Warneke CL, Clifton K, et al. Prognostic factors in patients with metastatic breast cancer with bone-only metastases. Oncologist. 2018;23(11):1282\u20138.","journal-title":"Oncologist."},{"key":"7593_CR7","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.jocn.2020.06.010","volume":"78","author":"S Terzi","year":"2020","unstructured":"Terzi S, Trentin F, Carretta E, et al. Breast cancer spinal metastases: prognostic factors affecting survival after surgery. A retrospective study. J Clin Neurosci. 2020;78:73\u20138.","journal-title":"J Clin Neurosci"},{"issue":"Suppl 16","key":"7593_CR8","doi-asserted-by":"publisher","first-page":"3867","DOI":"10.1002\/cncr.32832","volume":"126","author":"B Xu","year":"2020","unstructured":"Xu B, Hu X, Feng J, et al. Chinese expert consensus on the clinical diagnosis and treatment of advanced breast cancer (2018). Cancer. 2020;126(Suppl 16):3867\u201382.","journal-title":"Cancer."},{"issue":"2","key":"7593_CR9","doi-asserted-by":"publisher","first-page":"292","DOI":"10.7150\/jca.34572","volume":"11","author":"Z Wang","year":"2020","unstructured":"Wang Z, Chen M, Pan J, Wang X, Chen XS, Shen KW. Pattern of distant metastases in inflammatory breast cancer - a large-cohort retrospective study. J Cancer. 2020;11(2):292\u2013300 Published 2020 Jan 1.","journal-title":"J Cancer"},{"issue":"19","key":"7593_CR10","doi-asserted-by":"publisher","first-page":"10869","DOI":"10.1073\/pnas.191367098","volume":"98","author":"T Sorlie","year":"2001","unstructured":"Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A. 2001;98(19):10869\u201374.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"7593_CR11","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/BF01975440","volume":"18","author":"PG Koenders","year":"1991","unstructured":"Koenders PG, Beex LV, Langens R, Kloppenborg PW, Smals AG, Benraad TJ. Steroid hormone receptor activity of primary human breast cancer and pattern of first metastasis. The breast cancer study group. Breast Cancer Res Treat. 1991;18(1):27\u201332.","journal-title":"Breast Cancer Res Treat"},{"issue":"9","key":"7593_CR12","doi-asserted-by":"publisher","first-page":"3108","DOI":"10.1158\/0008-5472.CAN-07-5644","volume":"68","author":"M Smid","year":"2008","unstructured":"Smid M, Wang Y, Zhang Y, Sieuwerts AM, Yu J, Klijn JG, et al. Subtypes of breast cancer show preferential site of relapse. Cancer Res. 2008;68(9):3108\u201314.","journal-title":"Cancer Res"},{"issue":"1","key":"7593_CR13","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1093\/annonc\/mdu498","volume":"26","author":"NP Tobin","year":"2015","unstructured":"Tobin NP, Harrell JC, Lovrot J, Egyhazi BS, Frostvik SM, Carlsson L, et al. Molecular subtype and tumor characteristics of breast cancer metastases as assessed by gene expression significantly influence patient post-relapse survival. Ann Oncol. 2015;26(1):81\u20138.","journal-title":"Ann Oncol"},{"issue":"6","key":"7593_CR14","doi-asserted-by":"publisher","first-page":"djv048","DOI":"10.1093\/jnci\/djv048","volume":"107","author":"BA Kohler","year":"2015","unstructured":"Kohler BA, Sherman RL, Howlader N, Jemal A, Ryerson AB, Henry KA, et al. Annual report to the nation on the status of cancer, 1975\u20132011, featuring incidence of breast cancer subtypes by race\/ethnicity, poverty, and state. J Natl Cancer Inst. 2015;107(6):djv048.","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"7593_CR15","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1186\/s13058-017-0914-6","volume":"19","author":"HJ Parada","year":"2017","unstructured":"Parada HJ, Sun X, Fleming JM, Williams-DeVane CR, Kirk EL, Olsson LT, et al. Race-associated biological differences among luminal a and basal-like breast cancers in the Carolina breast cancer study. Breast Cancer Res. 2017;19(1):131.","journal-title":"Breast Cancer Res"},{"issue":"1","key":"7593_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/jcm3010001","volume":"3","author":"BT Li","year":"2014","unstructured":"Li BT, Wong MH, Pavlakis N. Treatment and prevention of bone metastases from breast cancer: a comprehensive review of evidence for clinical practice. J Clin Med. 2014;3(1):1\u201324.","journal-title":"J Clin Med"},{"key":"7593_CR17","unstructured":"Surveillance, Epidemiology, and End Results Program. Data use agreement for the 1975-2016 SEER research data file. https:\/\/seer.cancer.gov\/data\/sample-dua.html. Accessed 12 July 2019."},{"key":"7593_CR18","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1186\/s12885-016-2345-7","volume":"16","author":"J Diessner","year":"2016","unstructured":"Diessner J, Wischnewsky M, Stuber T, Stein R, Krockenberger M, Hausler S, et al. Evaluation of clinical parameters influencing the development of bone metastasis in breast cancer. BMC Cancer. 2016;16:307.","journal-title":"BMC Cancer"},{"issue":"3","key":"7593_CR19","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1007\/s10549-016-4066-7","volume":"161","author":"BA Leone","year":"2017","unstructured":"Leone BA, Vallejo CT, Romero AO, Machiavelli MR, Perez JE, Leone J, et al. Prognostic impact of metastatic pattern in stage IV breast cancer at initial diagnosis. Breast Cancer Res Treat. 2017;161(3):537\u201348.","journal-title":"Breast Cancer Res Treat"},{"key":"7593_CR20","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1038\/s41523-018-0054-x","volume":"4","author":"A Parkes","year":"2018","unstructured":"Parkes A, Clifton K, Al-Awadhi A, Oke O, Warneke CL, Litton JK, et al. Characterization of bone only metastasis patients with respect to tumor subtypes. NPJ Breast Cancer. 2018;4:2.","journal-title":"NPJ Breast Cancer"},{"issue":"8","key":"7593_CR21","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1007\/s10585-017-9871-9","volume":"34","author":"DJ Press","year":"2017","unstructured":"Press DJ, Miller ME, Liederbach E, Yao K, Huo D. De novo metastasis in breast cancer: occurrence and overall survival stratified by molecular subtype. Clin Exp Metastasis. 2017;34(8):457\u201365.","journal-title":"Clin Exp Metastasis"},{"issue":"4","key":"7593_CR22","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.jbo.2013.09.001","volume":"2","author":"I Kuchuk","year":"2013","unstructured":"Kuchuk I, Hutton B, Moretto P, Ng T, Addison CL, Clemons M. Incidence, consequences and treatment of bone metastases in breast cancer patients-experience from a single cancer Centre. J Bone Oncol. 2013;2(4):137\u201344.","journal-title":"J Bone Oncol"},{"issue":"9","key":"7593_CR23","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1038\/bjc.2015.127","volume":"112","author":"DJ Lobbezoo","year":"2015","unstructured":"Lobbezoo DJ, van Kampen RJ, Voogd AC, Dercksen MW, van den Berkmortel F, Smilde TJ, et al. Prognosis of metastatic breast cancer: are there differences between patients with de novo and recurrent metastatic breast cancer? Br J Cancer. 2015;112(9):1445\u201351.","journal-title":"Br J Cancer"},{"issue":"1","key":"7593_CR24","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1200\/JCO.2008.19.9844","volume":"28","author":"S Dawood","year":"2010","unstructured":"Dawood S, Broglio K, Buzdar AU, Hortobagyi GN, Giordano SH. Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: an institutional-based review. J Clin Oncol. 2010;28(1):92\u20138.","journal-title":"J Clin Oncol"},{"issue":"11","key":"7593_CR25","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1200\/JCO.2009.22.8775","volume":"28","author":"J Staaf","year":"2010","unstructured":"Staaf J, Ringner M, Vallon-Christersson J, Jonsson G, Bendahl PO, Holm K, et al. Identification of subtypes in human epidermal growth factor receptor 2--positive breast cancer reveals a gene signature prognostic of outcome. J Clin Oncol. 2010;28(11):1813\u201320.","journal-title":"J Clin Oncol"},{"issue":"21","key":"7593_CR26","doi-asserted-by":"publisher","first-page":"2492","DOI":"10.1001\/jama.295.21.2492","volume":"295","author":"LA Carey","year":"2006","unstructured":"Carey LA, Perou CM, Livasy CA, Dressler LG, Cowan D, Conway K, et al. Race, breast cancer subtypes, and survival in the Carolina breast cancer study. JAMA. 2006;295(21):2492\u2013502.","journal-title":"JAMA"},{"issue":"14","key":"7593_CR27","doi-asserted-by":"publisher","first-page":"2373","DOI":"10.1200\/JCO.2007.14.4287","volume":"26","author":"PL Nguyen","year":"2008","unstructured":"Nguyen PL, Taghian AG, Katz MS, Niemierko A, Abi RR, Boon WL, et al. Breast cancer subtype approximated by estrogen receptor, progesterone receptor, and HER-2 is associated with local and distant recurrence after breast-conserving therapy. J Clin Oncol. 2008;26(14):2373\u20138.","journal-title":"J Clin Oncol"},{"issue":"2","key":"7593_CR28","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1007\/s10549-017-4510-3","volume":"167","author":"D Cronin-Fenton","year":"2018","unstructured":"Cronin-Fenton D, Kjaersgaard A, Norgaard M, Amelio J, Liede A, Hernandez RK, et al. Breast cancer recurrence, bone metastases, and visceral metastases in women with stage II and III breast cancer in Denmark. Breast Cancer Res Treat. 2018;167(2):517\u201328.","journal-title":"Breast Cancer Res Treat"},{"issue":"2","key":"7593_CR29","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1001\/jama.2014.17322","volume":"313","author":"J Iqbal","year":"2015","unstructured":"Iqbal J, Ginsburg O, Rochon PA, Sun P, Narod SA. Differences in breast cancer stage at diagnosis and cancer-specific survival by race and ethnicity in the United States. JAMA. 2015;313(2):165\u201373.","journal-title":"JAMA"},{"issue":"9","key":"7593_CR30","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.1002\/cncr.27905","volume":"119","author":"M Chavez-Macgregor","year":"2013","unstructured":"Chavez-Macgregor M, Clarke CA, Lichtensztajn D, Hortobagyi GN, Giordano SH. Male breast cancer according to tumor subtype and race: a population-based study. Cancer. 2013;119(9):1611\u20137.","journal-title":"Cancer"},{"issue":"2","key":"7593_CR31","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1007\/s13524-011-0032-5","volume":"48","author":"MS Rendall","year":"2011","unstructured":"Rendall MS, Weden MM, Favreault MM, Waldron H. The protective effect of marriage for survival: a review and update. Demography. 2011;48(2):481\u2013506.","journal-title":"Demography"},{"issue":"6","key":"7593_CR32","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.3892\/mco.2014.400","volume":"2","author":"R Nishimura","year":"2014","unstructured":"Nishimura R, Osako T, Nishiyama Y, Tashima R, Nakano M, Fujisue M, et al. Prognostic significance of Ki-67 index value at the primary breast tumor in recurrent breast cancer. Mol Clin Oncol. 2014;2(6):1062\u20138.","journal-title":"Mol Clin Oncol"},{"issue":"2","key":"7593_CR33","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1159\/000475698","volume":"12","author":"M Gnant","year":"2017","unstructured":"Gnant M, Harbeck N, Thomssen C. St. Gallen\/Vienna 2017: a brief summary of the consensus discussion about escalation and De-escalation of primary breast cancer treatment. Breast Care (Basel). 2017;12(2):102\u20137.","journal-title":"Breast Care (Basel)"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-020-07593-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12885-020-07593-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-020-07593-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,13]],"date-time":"2020-11-13T08:09:14Z","timestamp":1605254954000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-020-07593-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,13]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["7593"],"URL":"https:\/\/doi.org\/10.1186\/s12885-020-07593-8","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.2.16521\/v5","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.2.16521\/v6","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.2.16521\/v3","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.2.16521\/v4","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.2.16521\/v1","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.2.16521\/v2","asserted-by":"object"}]},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,13]]},"assertion":[{"value":"11 October 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 October 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 November 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"We received permission from the National Cancer Institute, US to access the research data file in the SEER program (reference number 13114-Nov2018). Ethics approval was not applicable because SEER data is publicly available and without specific identifiers.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1102"}}